Alogliptin
alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3R)-3aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)yl}methyl) benzonitrile monobenzoate.Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Primary Characteristics
It is of Synthetic origin and belongs to benzonitrile monobenzoate.
It belongs to DPP-4 inhibitor pharmacological group on the basis of mechanism of action.
Molecular Weight: 461.51 · Solubility in Water: springly soluble · Solubility in Alcohol: springly solule · Non-proprietary name: Alogliptin.
Pharmacokinetics
Absorption: Alogliptin has an oral bioavailability is 100%.
Distribution: Alogliptin has a volume of distribution is 417 L,. plasma protein binding is 20%.
Elimination: it is metabolised via hepatic, plasma half-life is 21hrs, renal excretion is 76%.
Advertisement
Indications
Alogliptin is primarily indicated in conditions like Type II diabetes mellitus.
Contraindications
None recorded.
Dosage
Alogliptin's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 6.25 mg | 6.25 mg | — | PO | for patients with severe renal impairment |
| 12.5 mg | 12.5 mg | — | PO | for patient for moderate renal impairment |
| 25 mg | 25 mg | — | PO | Can be taken with or without food |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Alogliptin is known to cause more or less tolerable side effects which are usually transient. These include Headache, Nasopharyngitis, Upper respiratory tract infections.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.18.7.2 — Oral hypoglycemics